126 related articles for article (PubMed ID: 33559411)
21. Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol.
Teixeira JC; Vale DB; Bragança JF; Campos CS; Discacciati MG; Zeferino LC
BMC Public Health; 2020 Apr; 20(1):576. PubMed ID: 32345284
[TBL] [Abstract][Full Text] [Related]
22. Reduction of cervical cancer incidence within a primary HPV screening pilot project (WOLPHSCREEN) in Wolfsburg, Germany.
Horn J; Denecke A; Luyten A; Rothe B; Reinecke-Lüthge A; Mikolajczyk R; Petry KU
Br J Cancer; 2019 May; 120(10):1015-1022. PubMed ID: 30988395
[TBL] [Abstract][Full Text] [Related]
23. Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results.
Castle PE; Kinney WK; Xue X; Cheung LC; Gage JC; Poitras NE; Lorey TS; Katki HA; Wentzensen N; Schiffman M
J Natl Cancer Inst; 2019 Aug; 111(8):820-827. PubMed ID: 30576462
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women Above Age 30 Years.
Jin XW; Lipold L; Foucher J; Sikon A; Brainard J; Belinson J; Schramm S; Nottingham K; Hu B; Rothberg MB
J Gen Intern Med; 2016 Nov; 31(11):1338-1344. PubMed ID: 27418345
[TBL] [Abstract][Full Text] [Related]
25. Feasibility and acceptability of telehealth and contactless delivery of human papillomavirus (HPV) self-testing for cervical screening with Māori and Pacific women in a COVID-19 outbreak in Aotearoa New Zealand.
Bartholomew K; Grant J; Maxwell A; Bromhead C; Gillett F; Saraf R; Moodabe K; Sherman SM; McPherson G; Flower D; Kathuria J; Crengle S; Massey R; Scott N; Coote P
N Z Med J; 2022 Nov; 135(1565):83-94. PubMed ID: 36356272
[TBL] [Abstract][Full Text] [Related]
26. Human Papillomavirus (HPV) Self-Sampling among Never-and Under-Screened Indigenous Māori, Pacific and Asian Women in Aotearoa New Zealand: A Feasibility Study.
Bromhead C; Wihongi H; Sherman SM; Crengle S; Grant J; Martin G; Maxwell A; McPherson G; Puloka '; Reid S; Scott N; Bartholomew K
Int J Environ Res Public Health; 2021 Sep; 18(19):. PubMed ID: 34639352
[TBL] [Abstract][Full Text] [Related]
27. Comparison of cytology and human papillomavirus-based primary testing in cervical screening programs in the Nordic countries.
Partanen VM; Dillner J; Tropé A; Ágústsson ÁI; Pankakoski M; Heinävaara S; Sarkeala T; Wang J; Skare GB; Anttila A; Lönnberg S
J Med Screen; 2021 Dec; 28(4):464-471. PubMed ID: 33563086
[TBL] [Abstract][Full Text] [Related]
28. Human papillomavirus distribution and cervical cancer epidemiological characteristics in rural population of Xinjiang, China.
Wang Y; Cai YB; James W; Zhou JL; Rezhake R; Zhang Q
Chin Med J (Engl); 2021 Jul; 134(15):1838-1844. PubMed ID: 34267066
[TBL] [Abstract][Full Text] [Related]
29. He Tapu Te Whare Tangata (sacred house of humanity): Under-screened Māori women talk about HPV self-testing cervical screening clinical pathways.
Adcock A; Stevenson K; Cram F; MacDonald EJ; Geller S; Hermens J; Lawton B
Int J Gynaecol Obstet; 2021 Nov; 155(2):275-281. PubMed ID: 34382217
[TBL] [Abstract][Full Text] [Related]
30. Distinct Illness Representation Profiles Are Associated With Anxiety in Women Testing Positive for Human Papillomavirus.
McBride E; Marlow LAV; Chilcot J; Moss-Morris R; Waller J
Ann Behav Med; 2022 Jan; 56(1):78-88. PubMed ID: 33881145
[TBL] [Abstract][Full Text] [Related]
31. Should screening for cervical cancer go to primary human papillomavirus testing and eliminate cytology?
Swid MA; Monaco SE
Mod Pathol; 2022 Jul; 35(7):858-864. PubMed ID: 35256738
[TBL] [Abstract][Full Text] [Related]
32. Patterns of anxiety and distress over 12 months following participation in HPV primary screening.
Marlow LAV; McBride E; Ridout D; Forster AS; Kitchener H; Waller J
Sex Transm Infect; 2022 Jun; 98(4):255-261. PubMed ID: 34344834
[TBL] [Abstract][Full Text] [Related]
33. Colposcopy referral rates post-introduction of primary screening with human papillomavirus testing: evidence from a large British Columbia cohort study.
Gottschlich A; Gondara L; Smith LW; Anderson JJ; Cook D; Krajden M; Lee M; Martin RE; Melnikow J; Peacock S; Proctor L; Stuart G; Franco EL; van Niekerk D; Ogilvie GS
Lancet Reg Health Am; 2023 Oct; 26():100598. PubMed ID: 37786399
[TBL] [Abstract][Full Text] [Related]
34. Outcomes for Step-Wise Implementation of a Human Papillomavirus Testing-Based Cervical Screen-and-Treat Program in El Salvador.
Alfaro K; Maza M; Felix JC; Gage JC; Castle PE; Alonzo TA; Chacón A; González E; Soler M; Conzuelo-Rodriguez G; Masch R; Cremer M
JCO Glob Oncol; 2020 Oct; 6():1519-1530. PubMed ID: 33064628
[TBL] [Abstract][Full Text] [Related]
35. Current and prior human papillomavirus (HPV) type and cytology results enable risk assessment for triage to colposcopy.
Feldman S
BJOG; 2022 Dec; 129(13):2141. PubMed ID: 35871474
[No Abstract] [Full Text] [Related]
36. Emotional response to testing positive for human papillomavirus at cervical cancer screening: a mixed method systematic review with meta-analysis.
McBride E; Tatar O; Rosberger Z; Rockliffe L; Marlow LAV; Moss-Morris R; Kaur N; Wade K; Waller J
Health Psychol Rev; 2021 Sep; 15(3):395-429. PubMed ID: 32449477
[TBL] [Abstract][Full Text] [Related]
37. Human papillomavirus (HPV) testing for cervical cancer screening in a middle-income country: comment on a large real-world implementation study in China.
Thomsen LT; Kjær SK
BMC Med; 2021 Jul; 19(1):165. PubMed ID: 34261466
[No Abstract] [Full Text] [Related]
38. Implementing community-based human papillomavirus self-sampling with SMS text follow-up for cervical cancer screening in rural, southwestern Uganda.
Joseph NT; Namuli A; Kakuhikire B; Baguma C; Juliet M; Ayebare P; Ahereza P; Tsai AC; Siedner MJ; Randall TR; Ngonzi J; Boatin AA
J Glob Health; 2021; 11():04036. PubMed ID: 35003710
[TBL] [Abstract][Full Text] [Related]
39. The Capulana study: a prospective evaluation of cervical cancer screening using human papillomavirus testing in Mozambique.
Salcedo MP; Oliveira C; Andrade V; Mariano AAN; Changule D; Rangeiro R; Monteiro ECS; Baker E; Phoolcharoen N; Varon ML; Thomas JP; Castle PE; Fregnani JHTG; Schmeler KM; Lorenzoni C
Int J Gynecol Cancer; 2020 Sep; 30(9):1292-1297. PubMed ID: 32737122
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Oral Zinc Sulfate Supplementation on Clearance of Cervical Human Papillomavirus (HPV); A Randomized Controlled Clinical Trial.
Ayatollahi H; Rajabi E; Yekta Z; Jalali Z
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1285-1290. PubMed ID: 35485687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
